Companies › Shine-On Biomedical
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SOB100 HLA-G targeted exosome with anti-HLA-G VHH nanobody | HLA-G | Phase 1 | Healthy Subjects | Dec 2026 |
| SOA101 Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3 | CD274, HLA-G, CD3E | Phase 1 | Solid Tumors | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07219940 | SOB100 | Phase 1 | Healthy Subjects | Other | Dec 2026 |
| NCT07055594 | SOA101 | Phase 1 | Solid Tumors | Oncology | Feb 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.